High resolution accurate mass (HRAM) mass spectrometry

C. A. Crutchfield, William Clarke

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the past decade, mass spectrometry has grown from a primary use as an analytical method relegated to research or industrial applications to a method routinely applied in clinical settings. The utilization of mass spectrometry in a clinical setting requires accurate and robust measurement of diverse sets of analytes from a variety of matrices. The adoption of mass spectrometry in the clinic has certainly been slow because in many cases, there are large-scale immunoassay analyzers that meet the clinical requirements and can provide thousands of results for several assays every day. In many cases, immunoassay-based platforms can be more sensitive than mass spectrometers, though in recent years this divide is closing and in some cases mass spectrometry has surpassed immunoassays in this respect. However, there is a greater likelihood of analytical interference in immunoassay-based analyzers than mass spectrometers. This has caused some professional societies, such as the Endocrine Society, to mandate that in the near future steroid hormone levels be generated from a mass spectrometry based analyzer for consideration for publication in the Society Journal. This mandate comes at a time when the mass spectrometer has started to see considerable adoption in several clinical fields: small molecule analysis (e.g., toxicology), microbial identification, and molecular diagnostics. However, these fields may have not realized the clinical utility of mass spectrometry if not for the advent of high resolution mass spectrometry (HRMS).

Original languageEnglish (US)
Title of host publicationMass Spectrometry for the Clinical Laboratory
PublisherElsevier Inc.
Pages247-159
Number of pages89
ISBN (Print)9780128008713
DOIs
StatePublished - Nov 17 2016

Fingerprint

Mass Spectrometry
Immunoassay
Molecular Pathology
Toxicology
Publications
Steroids
Hormones
Research

Keywords

  • Clinical utility
  • Immunoassay analyzers
  • Interference
  • Mass spectrometry
  • Toxicology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Crutchfield, C. A., & Clarke, W. (2016). High resolution accurate mass (HRAM) mass spectrometry. In Mass Spectrometry for the Clinical Laboratory (pp. 247-159). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800871-3.00012-2

High resolution accurate mass (HRAM) mass spectrometry. / Crutchfield, C. A.; Clarke, William.

Mass Spectrometry for the Clinical Laboratory. Elsevier Inc., 2016. p. 247-159.

Research output: Chapter in Book/Report/Conference proceedingChapter

Crutchfield, CA & Clarke, W 2016, High resolution accurate mass (HRAM) mass spectrometry. in Mass Spectrometry for the Clinical Laboratory. Elsevier Inc., pp. 247-159. https://doi.org/10.1016/B978-0-12-800871-3.00012-2
Crutchfield CA, Clarke W. High resolution accurate mass (HRAM) mass spectrometry. In Mass Spectrometry for the Clinical Laboratory. Elsevier Inc. 2016. p. 247-159 https://doi.org/10.1016/B978-0-12-800871-3.00012-2
Crutchfield, C. A. ; Clarke, William. / High resolution accurate mass (HRAM) mass spectrometry. Mass Spectrometry for the Clinical Laboratory. Elsevier Inc., 2016. pp. 247-159
@inbook{0ac06193fa334298a664a315fba173cf,
title = "High resolution accurate mass (HRAM) mass spectrometry",
abstract = "Over the past decade, mass spectrometry has grown from a primary use as an analytical method relegated to research or industrial applications to a method routinely applied in clinical settings. The utilization of mass spectrometry in a clinical setting requires accurate and robust measurement of diverse sets of analytes from a variety of matrices. The adoption of mass spectrometry in the clinic has certainly been slow because in many cases, there are large-scale immunoassay analyzers that meet the clinical requirements and can provide thousands of results for several assays every day. In many cases, immunoassay-based platforms can be more sensitive than mass spectrometers, though in recent years this divide is closing and in some cases mass spectrometry has surpassed immunoassays in this respect. However, there is a greater likelihood of analytical interference in immunoassay-based analyzers than mass spectrometers. This has caused some professional societies, such as the Endocrine Society, to mandate that in the near future steroid hormone levels be generated from a mass spectrometry based analyzer for consideration for publication in the Society Journal. This mandate comes at a time when the mass spectrometer has started to see considerable adoption in several clinical fields: small molecule analysis (e.g., toxicology), microbial identification, and molecular diagnostics. However, these fields may have not realized the clinical utility of mass spectrometry if not for the advent of high resolution mass spectrometry (HRMS).",
keywords = "Clinical utility, Immunoassay analyzers, Interference, Mass spectrometry, Toxicology",
author = "Crutchfield, {C. A.} and William Clarke",
year = "2016",
month = "11",
day = "17",
doi = "10.1016/B978-0-12-800871-3.00012-2",
language = "English (US)",
isbn = "9780128008713",
pages = "247--159",
booktitle = "Mass Spectrometry for the Clinical Laboratory",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - High resolution accurate mass (HRAM) mass spectrometry

AU - Crutchfield, C. A.

AU - Clarke, William

PY - 2016/11/17

Y1 - 2016/11/17

N2 - Over the past decade, mass spectrometry has grown from a primary use as an analytical method relegated to research or industrial applications to a method routinely applied in clinical settings. The utilization of mass spectrometry in a clinical setting requires accurate and robust measurement of diverse sets of analytes from a variety of matrices. The adoption of mass spectrometry in the clinic has certainly been slow because in many cases, there are large-scale immunoassay analyzers that meet the clinical requirements and can provide thousands of results for several assays every day. In many cases, immunoassay-based platforms can be more sensitive than mass spectrometers, though in recent years this divide is closing and in some cases mass spectrometry has surpassed immunoassays in this respect. However, there is a greater likelihood of analytical interference in immunoassay-based analyzers than mass spectrometers. This has caused some professional societies, such as the Endocrine Society, to mandate that in the near future steroid hormone levels be generated from a mass spectrometry based analyzer for consideration for publication in the Society Journal. This mandate comes at a time when the mass spectrometer has started to see considerable adoption in several clinical fields: small molecule analysis (e.g., toxicology), microbial identification, and molecular diagnostics. However, these fields may have not realized the clinical utility of mass spectrometry if not for the advent of high resolution mass spectrometry (HRMS).

AB - Over the past decade, mass spectrometry has grown from a primary use as an analytical method relegated to research or industrial applications to a method routinely applied in clinical settings. The utilization of mass spectrometry in a clinical setting requires accurate and robust measurement of diverse sets of analytes from a variety of matrices. The adoption of mass spectrometry in the clinic has certainly been slow because in many cases, there are large-scale immunoassay analyzers that meet the clinical requirements and can provide thousands of results for several assays every day. In many cases, immunoassay-based platforms can be more sensitive than mass spectrometers, though in recent years this divide is closing and in some cases mass spectrometry has surpassed immunoassays in this respect. However, there is a greater likelihood of analytical interference in immunoassay-based analyzers than mass spectrometers. This has caused some professional societies, such as the Endocrine Society, to mandate that in the near future steroid hormone levels be generated from a mass spectrometry based analyzer for consideration for publication in the Society Journal. This mandate comes at a time when the mass spectrometer has started to see considerable adoption in several clinical fields: small molecule analysis (e.g., toxicology), microbial identification, and molecular diagnostics. However, these fields may have not realized the clinical utility of mass spectrometry if not for the advent of high resolution mass spectrometry (HRMS).

KW - Clinical utility

KW - Immunoassay analyzers

KW - Interference

KW - Mass spectrometry

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=85027186578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027186578&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800871-3.00012-2

DO - 10.1016/B978-0-12-800871-3.00012-2

M3 - Chapter

AN - SCOPUS:85027186578

SN - 9780128008713

SP - 247

EP - 159

BT - Mass Spectrometry for the Clinical Laboratory

PB - Elsevier Inc.

ER -